In the wake of a second quarter that saw revenues decline by 3.2%, contract research organization Charles River Laboratories is laying off 3% of its workforce, a spokesperson confirmed to Fierce Biotech in an emailed statement.

With its infectious disease blood test currently under review at the FDA, Inflammatix has obtained $57 million in new financing to help it gear up for its pending commercial rollout.

Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more selective and paced approach” to drug development.

Vironexis Biotherapeutics has unveiled with $26 million and a clinical-trial-ready gene therapy that has already nabbed FDA fast track and rare pediatric disease tags.

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

After F2G’s first attempt to get a brand-new class of antifungal to market was derailed by the FDA, the U.K.-based biotech has secured $100 million in fresh funding to bankroll another push towards commercialization next year.

Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 release. The facility is named the Pharma Research and Early Development (pRED) Center and houses about 1,000 state-of-the-art laboratory and office workplaces.

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, BeiGene has been accused of trade secrets theft by its old oncology rival AbbVie.

BridgeBio Pharma is slashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1/2 clinical trial. CEO Neil Kumar, Ph.D., said the data “are not yet transformational,” driving BridgeBio to shift its focus to other drug candidates and ways to treat disease.

SpectraWAVE has raised $50 million to support its approach to imaging the insides of clogged, plaque-filled blood vessels.